Symon Kaunda

Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

James Hakim, Victor Musiime, Alex J. Szubert et al. · New England Journal of Medicine · 2017 · 213 citations · Full text

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial

Nicholas I. Paton, Cissy Kityo, Immaculate Nankya et al. · The Lancet HIV · 2017 · 79 citations · Full text

Stavudine Toxicity in Adult Longer-Term ART Patients in Blantyre, Malawi

Joep J. van Oosterhout, Jane Mallewa, Symon Kaunda et al. · PLoS ONE · 2012 · 47 citations · Full text

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial

James Hakim, Cissy Kityo, Anne Hoppé et al. · The Lancet Infectious Diseases · 2017 · 41 citations · Full text

Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial

Jane Mallewa, Alexander J. Szubert, Peter Mugyenyi et al. · The Lancet HIV · 2018 · 29 citations · Full text